Emerging evidence supports the proposition that NEU1 can serve as a potential drug target for type 2 diabetes, wherein its activation may help rectify insulin resistance and check aberrations in glucose metabolism. The gene discussed is NEU1; the disease is type 2 diabetes mellitus.